Quest Diagnostics Q1 revenue rises 9.2%, boosts full-year EPS guidance

Quest Diagnostics reported a 9.2% increase in first-quarter revenue to $2.90 billion, driven by 9.0% organic growth. Adjusted diluted earnings per share rose 13.1% to $2.50, reflecting strong operational execution and innovation in diagnostic services. The company raised its full-year 2026 EPS guidance to a range of $10.63 to $10.83, supported by growth in advanced diagnostics and consumer health channels. Quest continues to invest in AI tools and strategic partnerships to expand its market reach and improve patient engagement.